Ignite Creation Date:
2024-05-11 @ 8:30 AM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06405425
Status:
RECRUITING
Last Update Posted:
2024-07-09
First Post:
2024-05-05
Brief Title:
A Study of BL-B01D1 PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Sponsor:
Sichuan Baili Pharmaceutical Co Ltd
Organization:
Sichuan Baili Pharmaceutical Co Ltd
Study Overview
Official Title:
A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 PD-1 Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 PD-1 combination therapy in patients with locally advanced or metastatic urothelial carcinoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None